Based on the data we have to date, in patients who have not received prior therapy for metastatic NSCLC, pembrolizumab could be offered as an alternative to platinum-doublet chemotherapy for those patients who express PD-L1 on ≥50% of their TCs based on the Keynote 024 trial. The gene discussed is CD274; the disease is non-small cell lung carcinoma.